# Phase II study of FOLFIRI with low-dose irinotecan plus ramucirumab as second-line treatment in Japanese patients with metastatic colorectal cancer (study rindo)

## TL;DR

This study tested a combination treatment for advanced colorectal cancer in Japanese patients and found it to be effective and safe.

## Contribution

The study evaluates FOLFIRI with low-dose irinotecan plus ramucirumab as a second-line treatment for Japanese patients with metastatic colorectal cancer.

## Key findings

- Median progression-free survival was 5.9 months and overall survival was 17.0 months.
- The treatment achieved a disease control rate of 74% with manageable adverse events.
- Low-dose irinotecan combined with ramucirumab was safely administered without reducing therapeutic effectiveness.

## Abstract

This multicenter, single-arm, Phase II study aimed to evaluate the efficacy and safety of fluorouracil, levofolinate, and irinotecan (150 mg/m2, standard dose in Japan) (FOLFIRI) plus ramucirumab (RAM) as second-line treatment for metastatic colorectal cancer (mCRC) in Japanese patients.

On Day 1 of each 2-week cycle, patients with unresectable mCRC who were refractory to oxaliplatin and fluoropyrimidine in combination with bevacizumab or anti-epidermal growth factor receptor antibodies as first-line treatment received 8 mg/kg RAM, followed by the FOLFIRI regimen with low-dose irinotecan (150 mg/m2). The primary endpoint was progression-free survival (PFS), and secondary endpoints were overall survival (OS), treatment compliance, and safety.

A total of 62 patients were enrolled from 15 institutions between January 2018 and August 2021. The intent-to-treat and safety populations included 61 and 58 patients. Median PFS and OS were 5.9 months (95% CI, 4.8–6.9 months) and 17.0 months (95% CI, 12.0–21.0 months), respectively. The objective response rate and disease control rate were 8.2% and 74%, respectively. The median time to treatment failure was 4.8 months (95% CI, 3.2–5.9 months). The median relative dose intensities of irinotecan, 5-fluorouracil, and RAM were 73.8% (range, 40.3%–102.4%), 58.5% (range, 22.8%–102.4%), and 80.8% (range, 36.1%–102.4%), respectively. Frequencies of Grade ≥ 3 hematologic, non-hematologic, and RAM-associated adverse events were 43%, 24%, and 17%, respectively. The observed Grade ≥ 3 adverse events included neutropenia (40%), diarrhea (8.6%), decreased appetite (10%), hypertension (6.9%), and proteinuria (3.4%).

FOLFIRI with low-dose irinotecan plus RAM is a feasible second-line treatment in Japanese patients with mCRC.

FOLFIRI plus RAM therapy performed in the setting of irinotecan 150 mg/m2 can be safely administered without decreasing the therapeutic effect and achieve good survival.